What is the clinical evidence from this study?

Study design: Cohort. Population: Postoperative breast cancer (n=1934). Intervention: Anthracycline-based chemotherapy (FEC) vs. Taxane-containing regimens (TC, AC-T, EC-T). Primary outcome: Incidence of newly diagnosed dyslipidemia after chemotherapy (p=<.001).

August 13, 2020Open Access

Adjuvant chemotherapy-associated lipid changes in breast cancer patients

Q: What are the key findings of this study?

Anthracycline-based chemotherapy regimens (FEC) were associated with a lower incidence of newly diagnosed dyslipidemia compared to taxane-containing regimens (TC, AC-T, EC-T) (P < 0.001).

Key Result

Anthracycline-based chemotherapy regimens (FEC) were associated with a lower incidence of newly diagnosed dyslipidemia compared to taxane-containing regimens (TC, AC-T, EC-T) (P < 0.001).

Study Design

Type

Cohort (n=1,934)

Structured PICO

Do different adjuvant chemotherapy regimens cause varying alterations in serum lipids in postoperative breast cancer patients?

Population

1,934 consecutive postoperative breast cancer patients who received chemotherapy regimens, evaluated for serum lipid alterations.

Exposure

Adjuvant chemotherapy regimens (including FEC, TC, AC-T, and EC-T)

Comparator

Comparison between different chemotherapy regimens (FEC vs TC, AC-T, and EC-T)

Outcome

Alterations in serum lipids (TG, TC, HDL-C, LDL-C) pre- and post-chemotherapysurrogate

Breast cancer patients receiving chemotherapy experience elevated lipid profiles, with anthracycline-based regimens showing fewer adverse lipid effects compared to taxane-containing regimens.

Main Result

p-value: p=<.001

Abstract

Adjuvant chemotherapy may cause alterations in serum lipids in postoperative breast cancer (BC) patients, but the specific alterations caused by different chemotherapy regimens remain unclear. The aim of this study was to investigate the status of serum lipids pre- and post-chemotherapy and to compare the side effects of different chemotherapy regimens on serum lipid.We retrospectively analysed the lipid profiles of 1934 consecutive postoperative BC patients who received one of the following chemotherapy regimens:The levels of triglycerides (TG), total cholesterols (TC), and low-density lipoprotein (LDL-C) were significantly elevated in patients who received chemotherapy regimens above (P 24 was associated with abnormal lipid profiles (TG, TC, HDL-C, LDL-C) post-chemotherapy compared with BMI ≤ 24 (P < .001; P = .036; P = .012; P = .048, respectively).BC patients receiving chemotherapy may have elevated lipid profiles, and anthracycline-based regimen had less side effects on lipid profiles compared with regimens containing taxane. Therefore, it is necessary to take lipid metabolism into consideration when making chemotherapy decisions and dyslipidemia prevention and corresponding interventions are indispensable during the whole chemotherapy period.

AI से पूछें

Bookmark

View Full Paper